Statkevich P - Search Results

1

Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.

Zhao Y, Hu Z, Bathena SP, Keidel S, Miller-Moslin K, Statkevich P, Bello A, Roy A, Suryawanshi S. Zhao Y, et al. Among authors: statkevich p. Clin Cancer Res. 2024 Jul 15;30(14):3050-3058. doi: 10.1158/1078-0432.CCR-23-2396. Clin Cancer Res. 2024. PMID: 38295151 Free PMC article.

2

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.

Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA, Larkin J, Sznol M, Franke F, Ciuleanu TE, Pereira C, Muñoz Couselo E, Bronzon Damian F, Schenker M, Perfetti A, Lebbe C, Quéreux G, Meier F, Curti BD, Rojas C, Arriaga Y, Yang H, Zhou M, Ravimohan S, Statkevich P, Tagliaferri MA, Khushalani NI. Diab A, et al. Among authors: statkevich p. J Clin Oncol. 2023 Oct 20;41(30):4756-4767. doi: 10.1200/JCO.23.00172. Epub 2023 Aug 31. J Clin Oncol. 2023. PMID: 37651676 Free PMC article. Clinical Trial.

3

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.

Khushalani NI, Diab A, Ascierto PA, Larkin J, Sandhu S, Sznol M, Koon HB, Jarkowski A, Zhou M, Statkevich P, Geese WJ, Long GV. Khushalani NI, et al. Among authors: statkevich p. Future Oncol. 2020 Oct;16(28):2165-2175. doi: 10.2217/fon-2020-0351. Epub 2020 Jul 29. Future Oncol. 2020. PMID: 32723187 Clinical Trial.

4

Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.

Zhao X, Shen J, Ivaturi V, Gopalakrishnan M, Feng Y, Schmidt BJ, Statkevich P, Goodman V, Gobburu J, Bello A, Roy A, Agrawal S. Zhao X, et al. Among authors: statkevich p. Ann Oncol. 2020 Feb;31(2):302-309. doi: 10.1016/j.annonc.2019.10.015. Epub 2019 Dec 9. Ann Oncol. 2020. PMID: 31959348 Free article.

5

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies.

Zhang J, Sanghavi K, Shen J, Zhao X, Feng Y, Statkevich P, Sheng J, Roy A, Zhu L. Zhang J, et al. Among authors: statkevich p. CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):962-970. doi: 10.1002/psp4.12476. Epub 2019 Dec 1. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31710163 Free PMC article.

6

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors.

Sanghavi K, Zhang J, Zhao X, Feng Y, Statkevich P, Sheng J, Roy A, Vezina HE. Sanghavi K, et al. Among authors: statkevich p. CPT Pharmacometrics Syst Pharmacol. 2020 Jan;9(1):29-39. doi: 10.1002/psp4.12477. Epub 2019 Dec 1. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 31709718 Free PMC article.

7

Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance.

Hamuro L, Statkevich P, Bello A, Roy A, Bajaj G. Hamuro L, et al. Among authors: statkevich p. Clin Pharmacol Ther. 2019 Nov;106(5):1018-1027. doi: 10.1002/cpt.1502. Epub 2019 Jul 10. Clin Pharmacol Ther. 2019. PMID: 31090921

8

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.

Mita MM, Mita AC, Moseley JL, Poon J, Small KA, Jou YM, Kirschmeier P, Zhang D, Zhu Y, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig SJ, Bannerji R, Shapiro GI. Mita MM, et al. Among authors: statkevich p. Br J Cancer. 2017 Oct 24;117(9):1258-1268. doi: 10.1038/bjc.2017.288. Epub 2017 Aug 31. Br J Cancer. 2017. PMID: 28859059 Free PMC article. Clinical Trial.

9

Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.

Bajaj G, Gupta M, Feng Y, Statkevich P, Roy A. Bajaj G, et al. Among authors: statkevich p. J Clin Pharmacol. 2017 Dec;57(12):1527-1533. doi: 10.1002/jcph.962. Epub 2017 Aug 11. J Clin Pharmacol. 2017. PMID: 28800166 Free PMC article. No abstract available.

10

No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.

Anderson MS, Kosoglou T, Statkevich P, Li J, Rotonda J, Meehan AG, Cutler DL. Anderson MS, et al. Among authors: statkevich p. Clin Pharmacol Drug Dev. 2018 Feb;7(2):143-150. doi: 10.1002/cpdd.354. Epub 2017 Apr 12. Clin Pharmacol Drug Dev. 2018. PMID: 28403576 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters